192 related articles for article (PubMed ID: 2133113)
1. C-MYC: evidence for multiple regulatory functions.
Penn LJ; Laufer EM; Land H
Semin Cancer Biol; 1990 Feb; 1(1):69-80. PubMed ID: 2133113
[TBL] [Abstract][Full Text] [Related]
2. The myc gene family proteins and their role in transformation and differentiation.
Ingvarsson S
Semin Cancer Biol; 1990 Dec; 1(6):359-69. PubMed ID: 2103508
[TBL] [Abstract][Full Text] [Related]
3. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
4. Analysis of c-Myc and Max binding to the c-myc promoter: evidence that autosuppression occurs via an indirect mechanism.
Buckle RS; Méchali M
Oncogene; 1995 Mar; 10(6):1249-55. PubMed ID: 7700652
[TBL] [Abstract][Full Text] [Related]
5. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
[TBL] [Abstract][Full Text] [Related]
6. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
Lüscher B; Larsson LG
Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
[TBL] [Abstract][Full Text] [Related]
7. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of the N-terminal domain of the Myc oncoprotein.
Oster SK; Mao DY; Kennedy J; Penn LZ
Oncogene; 2003 Apr; 22(13):1998-2010. PubMed ID: 12673205
[TBL] [Abstract][Full Text] [Related]
9. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions.
Koskinen PJ; Ayer DE; Eisenman RN
Cell Growth Differ; 1995 Jun; 6(6):623-9. PubMed ID: 7669717
[TBL] [Abstract][Full Text] [Related]
10. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
[TBL] [Abstract][Full Text] [Related]
11. Translocations involving c-myc and c-myc function.
Boxer LM; Dang CV
Oncogene; 2001 Sep; 20(40):5595-610. PubMed ID: 11607812
[TBL] [Abstract][Full Text] [Related]
12. c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene.
Kuschak TI; Kuschak BC; Taylor CL; Wright JA; Wiener F; Mai S
Oncogene; 2002 Jan; 21(6):909-20. PubMed ID: 11840336
[TBL] [Abstract][Full Text] [Related]
13. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
[TBL] [Abstract][Full Text] [Related]
14. c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation.
La Rocca SA; Crouch DH; Gillespie DA
Oncogene; 1994 Dec; 9(12):3499-508. PubMed ID: 7970710
[TBL] [Abstract][Full Text] [Related]
15. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
[TBL] [Abstract][Full Text] [Related]
16. c-Myc does not require max for transcriptional activity in PC-12 cells.
Ribon V; Leff T; Saltiel AR
Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of Nmi, a novel partner of Myc proteins.
Bao J; Zervos AS
Oncogene; 1996 May; 12(10):2171-6. PubMed ID: 8668343
[TBL] [Abstract][Full Text] [Related]
19. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
[TBL] [Abstract][Full Text] [Related]
20. Definition of the activities and properties of c-myc required to inhibit cell differentiation.
Freytag SO; Dang CV; Lee WM
Cell Growth Differ; 1990 Jul; 1(7):339-43. PubMed ID: 2278885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
